Case Reports in Oncology · 2021 · 11 citations · 11 references
MedicineOncologyPharmacologyCancer ImmunologyClinical ImmunologyImmunotherapyCancer ImmunotherapyCombination ImmunotherapyImmune-related Adverse EventsImmunosuppressionImmunotherapy SafetyLung CancerAcute Adrenal InsufficiencyAdrenal Insufficiency PharmacotherapyImmune-related Adverse Event AssessmentImmune-related Adverse Event GradingNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPembrolizumab Therapy
Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE.
11
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations